Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204940 · ClinicalTrials.gov registry record
Longitudinal Observational Biomarker Study
A clinical trial, sponsored by Centre for Addiction and Mental Health.
- Completed
- Registry status
- 506
- Enrollment target
NCT05204940: Completed study, sponsored by Centre for Addiction and Mental Health.
NCT05204940 is a clinical trial that has completed, run by Centre for Addiction and Mental Health. The registered enrollment target is 506 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05204940 has completed, sponsored by Centre for Addiction and Mental Health.
- COMPLETED
- Registry status
- 506 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
Primary Outcome
To test whether persistent (non-remitting) depression has the ability to change cognition and lead to greater cognitive decline, and greater degradation of neural circuitry
Interventions
- BEHAVIORAL Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)
- BEHAVIORAL Neuropsychological Data
- BEHAVIORAL Clinical Scales
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2024-07-31 |
What the finished NCT05204940 record still lists
NCT05204940 is an observational study that tracks outcomes without assigning an intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI) is the first listed.
NCT05204940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05204940 about?
NCT05204940 is a clinical study titled "Longitudinal Observational Biomarker Study". The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
What is the current status of trial NCT05204940?
This trial is currently completed. The enrollment target is 506 participants. The study started on 2017-09-27. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05204940?
The interventions under investigation include: Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI) (BEHAVIORAL), Neuropsychological Data (BEHAVIORAL), Clinical Scales (BEHAVIORAL).
Who is sponsoring clinical trial NCT05204940?
This trial is sponsored by Centre for Addiction and Mental Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI